Prominent EPs oppose Guidant plea deal
This article was originally published in The Gray Sheet
Executive Summary
Doctors who first alerted FDA in 2005 to a heightened risk for some Guidant implantable defibrillators to short circuit have written a Minnesota District Court judge in opposition to a plea agreement between Boston Scientific/Guidant and the U.S. Department of Justice. Judge Donovan Frank has yet to rule on whether to accept the guilty plea to two misdemeanor counts of making false statements and failing to notify FDA on issues related to revisions and malfunctions with two ICDs (1"The Gray Sheet" April 12, 2010). "We are extremely dismayed by the U.S. Attorney General's decision to enter into a plea agreement with Guidant LLC, rather than prosecute the company and the individuals responsible for the egregious act," write cardiologists Robert Hauser and Barry Maron, both of the Minneapolis Heart Institute, in an April 12 2letter. "To allow a repeat offender like Guidant to escape with a fine (that is entirely borne by the shareholders of Boston Scientific) does not hold the guilty parties fully accountable and inevitably undermines patient safety." The doctors treated a 21-year-old patient who died in 2005 after his Prizm 2 failed to deliver a needed shock
You may also be interested in...
Judge Delays Acceptance Of Boston Scientific Guilty Plea In Guidant ICD Case
Boston Scientific's hopes of putting one significant source of Guidant-inherited legal troubles behind it hit at least a short delay last week
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.